Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: Correlation with clinical outcome of anti‐estrogen therapy
- 1 April 1991
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 47 (6) , 827-832
- https://doi.org/10.1002/ijc.2910470606
Abstract
We have studied the estradiol sensitivity of primary human breast carcinomas in organ culture in a prospective pilot series of 109 tumors. The effect on plasminogen activator (PA) production was used as the end‐point of estrogen action. We found that: (i) All tumors secreted detectable levels of urokinase‐type PA (uPA); the level of basal uPA production was markedly heterogeneous but showed a weak association with the level of estrogen receptor positivity (p = 0.049). (ii) Only 23.5% of the tumors secreted tissue‐type PA (tPA) in addition to uPA; a higher proportion of these tumors had histological characteristics indicative of good prognosis (18% vs. 3% of tumors secreting only uPA). (iii) Estradiol modulated uPA production and this effect was receptor‐mediated, (iv) Responsiveness to estradiol was limited to a subset (25 of 60 or 41.7%) of estrogen and progesterone‐receptor‐positive tumors, (v) Of 20 evaluable patients with lymph‐node and receptor‐positive breast cancer who received adjuvant anti‐estrogen therapy, 11 were identified as estradiol‐sensitive by the in vitro PA assay; of these, 10 had no evidence of disease after a median follow‐up period of 3+ years. In contrast, of 9 patients with tumors identified as estradiol‐insensitive, 4 developed metastases within 3+ years of follow‐up. (vi) Consistent with the previously reported inhibitory effect of corticosteroids on uPA production in organ cultures of human tumors, the basal culture level of uPA produced by tumors from patients receiving corticosteroids at the time of surgery was significantly lower than the level of uPA in the remaining tumors (p = 0.029). Also, tumors from patients receiving thyroid hormone, known to stimulate uPA in vitro, showed a slight trend toward increased production of uPA. These results show that hormone effects on tumor PA production are qualitatively similar in organ culture and in the host. This and the emerging individual correlation between sensitivity to estradiol in vitro, as determined by PA, and the clinical effectiveness of anti‐estrogen therapy, underscore the potential usefulness of the organ culture approach.Keywords
This publication has 15 references indexed in Scilit:
- UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTIGEN AND EARLY RELAPSE IN BREAST CANCERThe Lancet, 1989
- Influence of L-thyroxine on cardiac function in athyreotic thyroid cancer patients — An echophonocardiographic studyJournal of Molecular Medicine, 1988
- Plasminogen activator expression and steroid hormone receptors in female breast cancer: A multifactorial studyInternational Journal of Cancer, 1988
- Plasminogen activator dependent pathways inthe dissemination of human tumor cells in the chick embryoCell, 1988
- The estrogen-regulated 52K-cathepsin-D in breast cancer: From biology to clinical applicationsInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1987
- Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomasInternational Journal of Cancer, 1984
- The regulation of tissue plasminogen activator activity by human fibroblastsCell, 1983
- Retention of glucocorticoid by isolated mammary tissue may complicate interpretation of results from invitro experimentsBiochemical and Biophysical Research Communications, 1979
- Androgen-dependent fibrinolytic activity in a murine mammary carcinoma (shionogi SC-115 cells) in vitroCell, 1976
- Predicting Response to Endocrine Therapy in Human Breast Cancer: A HypothesisScience, 1975